Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for Psychosis in Alzheimer's Disease
NCT00034762Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 2000
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of risperidone in Alzheimer's disease (AD), sponsored by Johnson & Johnson. Started Dec 2000; status: completed.
02
Drugs
risperidone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00034762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034762.